Nanobiotix SA

Voting Rights and Shares Capital of the Company

08 يونيو 2023 16:15:00 بحسب Nasdaq GlobeNewswire

NANOBIOTIX Provides First Quarter 2023 Operational and Financial Update

17 مايو 2023 16:15:00 بحسب Nasdaq GlobeNewswire

NANOBIOTIX Entering Final Contract Negotiations Following Agreement to Non-Binding Term Sheet for Development and Commercialization of NBTXR3 With a Major Global Pharmaceutical Company

05 مايو 2023 01:30:00 بحسب Nasdaq GlobeNewswire

NANOBIOTIX Provides Business Update and Reports Full Year 2022 Financial Results

24 أبريل 2023 19:33:54 بحسب Nasdaq GlobeNewswire

NANOBIOTIX to Provide Operational Update and Report Full Year 2022 Financial Results on April 24, 2023

17 أبريل 2023 16:15:00 بحسب Nasdaq GlobeNewswire

Voting Rights and Shares Capital of the Company

11 أبريل 2023 16:15:00 بحسب Nasdaq GlobeNewswire

Nanobiotix to Postpone Full Year 2022 Financial Results and Conference Call

27 مارس 2023 16:15:00 بحسب Nasdaq GlobeNewswire

Nanobiotix to Provide Operational Update and Report Full Year 2022 Financial Results on March 28, 2023

14 مارس 2023 16:15:00 بحسب Nasdaq GlobeNewswire

Voting Rights and Shares Capital of the Company

14 فبراير 2023 16:15:00 بحسب Nasdaq GlobeNewswire

Voting Rights and Shares Capital of the Company

11 يناير 2023 16:15:00 بحسب Nasdaq GlobeNewswire

NANOBIOTIX Announces First Patient Randomized in the United States in Global Phase 3 Pivotal Trial Evaluating Radioenhancer NBTXR3 in Head and Neck Cancer

27 ديسمبر 2022 01:45:00 بحسب Nasdaq GlobeNewswire